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Objective: The objective of the present work was to formulate the solid dispersions of simvastatin for enhancement of its aqueous solubility and 
dissolution rate.  
Methods: In the present study, solid dispersions of simvastatin were prepared by Kneading and Solvent evaporation methods. The polymeric 
carriers like Polyethylene glycol (PEG) 6000 and Polyvinyl Pyrrolidone (PVP) K30 were used in different ratios (ratio of drug: carrier was 1:1, 1:2) 
to formulate solid dispersions. The prepared solid dispersions were characterized by differential scanning calorimetry (DSC), Fourier transforms 
infrared spectroscopy (FTIR), and evaluated for drug content, percentage yield, saturation solubility, in vitro dissolution studies. The best formula of 
the solid dispersion was selected according to the solubility and dissolution data. 
Results: The F7 formulation was found to be an optimized formulation containing PVP K30 in the ratio 1:1 prepared by solvent evaporation 
technique. The Drug content was found to be higher i.e. 94.89 in the F7 batch. The FT-IR spectra revealed that there was no interaction between 
drugs and carriers. DSC thermogram indicated entrapment of simvastatin in PVP K30 and the conversion of crystalline simvastatin into an 
amorphous form. The F7 formulation showed maximum drug release i.e. 98.60% in 60 min which is 2 times greater than pure drug making it an 
optimized formulation. 
Conclusion: The solubility of simvastatin was successfully enhanced through the solid dispersion technique. Solid dispersions prepared with 
solvent evaporation method were more soluble than solid dispersions prepared with kneading method with carrier PVP K30.  
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INTRODUCTION 
Near about 35-40% of new chemical entities possess the problem of 
low aqueous solubility that affects drug absorption in the 
gastrointestinal tract (GIT) which leads to lower bioavailability, high 
inter and intrasubject variability, dose dumping chances, reduction 
in the effectiveness of the medication, and lastly, formulation 
development get collapsed [1]. In such cases, scientists look for 
better formulations that will improve solubility and thus dissolution 
and bioavailability get improved. Various strategies involved are 
micronization, salt formation, solubilization, self-micro emulsifying 
drug delivery system, complexation, prodrug approaches, 
dendrimers formation, spray drying, solid solution/solid dispersion 
with hydrophilic carriers, nano-particular systems [2]. 
According to the Biopharmaceutical Classification System (BCS), oral 
medications are classified into four classes based on their solubility 
and permeability characteristics. Out of the four classes, class II and 
class IV possess the problem of low aqueous solubility, so there is a 
need to improve solubility by using different solubility enhancement 
techniques to improve in vitro dissolution and bioavailability of 
medications [3]. Solid dispersion is gaining more focus in few 
decades. Solid dispersion is defined as a group of solid products 
consisting of at least two components, hydrophobic drug, and 
hydrophilic carrier. The term dispersion means a hydrophobic drug 
is dispersed in an inert hydrophilic matrix [4]. 
Simvastatin is a Cholesterol-lowering, hydrophobic drug having a 
log P value of 4. It is a BCS Class II drug with low aqueous solubility 
(30 µg/ml). It is a white crystalline powder. It acts as a specific 
potent inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG 
CoA) reductase which reduces HMG CoA to mevalonate thus 
blocking vital steps for cholesterol biosynthesis in the liver, so it is 
extensively employed in the treatment of hypercholesterolemia and 
dyslipidemia. The structure of simvastatin is shown in fig. 1 [5, 6]. 
In the present research, trials were taken to improve the solubility 
and thus dissolution rate of simvastatin by formulating its solid 
dispersions. Different concentrations of carriers were used for 
preparing solid dispersions and prepared free-flowing dispersions 
then evaluated for Solubility, FT-IR, and DSC analysis. 
 
 
Fig. 1: Structure of simvastatin 
 
MATERIALS AND METHODS 
Materials 
Simvastatin gift sample was obtained from Cipla Pvt. Ltd. (Mumbai). 
Polyvinyl pyrrolidone K30 has been purchased from Loba Chemie 
Pvt. Ltd. Mumbai. Polyethylene glycol 6000, Ethanol was obtained 
from Research Lab Fine Chemical Industries Pvt. Ltd. (Mumbai). 
Other chemicals and reagents were of analytical grade.  
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Methods 
Physicochemical characterization of drug 
The Drug was identified by various physicochemical properties 
such as Color, Odour, Melting point, DSC analysis, and FT-IR 
spectroscopy [7]. 
Determination of saturation solubility of simvastatin 
Solubility of simvastatin was determined by the shake flask method 
in different solvents like water, ethanol, methanol, chloroform, 
phosphate buffer pH 6.8, and phosphate buffer pH 7.4. Saturated 
solutions of simvastatin were prepared in different solvents and 
were stirred for 24 h using a rotary shaker. The solution was then 
filtered through Whatmann filter paper. The concentration of 
simvastatin was determined using a UV spectrophotometer against 
the respective solvent as blank at λmax of drug [8]. 
Preparation of calibration curve in ethanol 
The stock solution was prepared by taking accurately weighed 100 
mg of simvastatin in a 100 ml volumetric flask and dissolving it in 
ethanol and volume made up to the 100 ml mark. The concentration 
of the solution was 1000 µg/ml. From the stock solution, 1 ml was 
pipetted in a 10 ml volumetric flask and the volume was made up to 
mark with distilled water to obtain the concentration of 100 µg/ml. 
This was a working standard solution. from this solution, 0.5, 1, 1.5, 
2, 2.5 and 3 ml were pipetted in separate 10 ml volumetric flasks 
and diluted up to mark with distilled water to get final 
concentrations of 5,10,15,20,25,30 µg/ml. The Samples were 
measured spectrophotometrically at λmax of a drug against ethanol 
as a blank. Absorbance values were plotted against concentrations of 
the drug to obtain a calibration curve [9]. 
Preparation of solid dispersions (SDs) 
Solid dispersions of simvastatin were prepared using kneading and 
solvent evaporation methods employing PEG 6000 and PVP K30 as 
carriers. Prepared solid dispersions (SDs) were compared with pure 
drug and physical mixtures of drug and polymer.  
Physical mixture 
Simvastatin and carriers (PEG 6000, PVP K30) were mixed in mortar 
and pestle to obtain physical mixtures. 
Kneading method 
Drug and carriers (PEG 6000 and PVP K30) were mixed in different 
ratios i.e. 1:1, 1:2. A small amount of solvent (ethanol) was added 
into the mixture of drug and carrier until the formation of paste. 
Then that obtained paste was kneaded for few minutes and dried in 
an oven at 40 °C. The dried mass was then ground and sieved 
through sieve No. 80. The formulations were encoded as F1, F2, F3, 
and F4. F1 and F2 for PEG SDs and later for PVP SDs [10]. 
Solvent evaporation method 
Solid dispersions of simvastatin in PEG 6000 and PVP K30 prepared 
by solvent evaporation method with ratios 1:1 and 1:2 were denoted 
by F5, F6, F7, and F8 respectively. The required amount of carrier 
dissolved in a sufficient quantity of ethanol. To this, the solution of 
the drug was added with continuous stirring until the formation of a 
clear solution. The solvent then evaporated leaving behind solidified 
mass. The mass was dried, grounded, and sifted through sieve No. 
80. The prepared dispersions were then characterized [11]. 
Characterization of solid dispersions  
Saturation solubility determination 
The Shake flask method was used for the determination of the 
solubility of prepared solid dispersions. The excessive quantity of 
prepared SDs was added in a glass stoppered flask containing 25 ml 
of solvent and flasks were shaken for 24 h at 37±0.5 °C. After 24 h, 
the solution was filtered, diluted appropriately and absorbance was 
taken at the λmax of a drug. Analysis of each sample was carried out 
in triplicate. The Change in solubility value was compared with pure 
drug solubility.  
Determination of percentage yield 
The Percentage yield of F1 to F8 formulations was calculated by 
using the following equation [12]. Determination was carried out in 
triplicate 
% yield = Actual weight of solid dispersion
Total weight of drug and carrier
× 100 
Estimation of drug content 
The Solid dispersion equivalent to 10 mg of drug was dissolved in 10 
ml of ethanol, filtered, diluted, and drug content was determined 
using UV spectrophotometer at λmax of a drug against ethanol as a 
blank. Analysis of each sample was carried out in triplicate [13]. 
Fourier transform infrared spectroscopy 
By using FT-IR Spectrophotometer (FT-IR 8400S, Shimadzu), 
compatibility studies of drugs and carriers were carried out. FTIR 
spectra of SDs and physical mixture were obtained by the potassium 
bromide method in which powder is scanned in the range of 4000-
400 cm-1 with resolution 1 cm-1
DSC analysis 
 [14].  
DSC thermographs of the physical mixture, solid dispersion were 
obtained using the Mettler-Toledo instrument. Samples were sealed 
in pierced aluminum pans and heated to a scanning rate of 10 
°C/min over the temperature range of 40-350 °C. The inert 
atmosphere in the chamber was maintained by providing nitrogen 
gas at a flow rate of 40 ml/min [15]. 
In vitro dissolution studies  
The in vitro Dissolution data was obtained by using USP Type II 
(Paddle type) dissolution apparatus with a rotating speed of 100 
rpm and the media used was 900 ml phosphate buffer pH 6.8 
maintained at 37±0.5 °C. Sample equivalent to 40 mg added in 
dissolution media. At specific time intervals i.e. after every 10 min, a 
5 ml sample was pipetted, and an equal amount of fresh media was 
added. Pipetted samples were filtered, diluted, and analyzed by UV 
spectrophotometer at λmax of drug [16]. Analysis of each sample 
was carried out in triplicate.  
RESULTS AND DISCUSSION 
The Drug was found to be in solid, off-white powdered form. The 
melting point was determined by the capillary method and it was 
found to be in the range of 138-140 °C which is the same as the 
standard reported melting point [17]. 
Being a class II drug, simvastatin having low aqueous solubility. 
Solubility was found to be 0.028 mg/ml in distilled water, 0.125 
mg/ml in ethanol, 0.118 mg/ml in methanol, 0.619 mg/ml in 
chloroform, 2.418 mg/ml in phosphate buffer 6.8 and 0.865 mg/ml 
in phosphate buffer 7.4.  
The calibration curve was done by using a UV–spectrophotometer. 
Absorbance maxima (λmax) was found to be at 238 nm, so the 
calibration curve was prepared in ethanol at 238 nm. [18]. The plot 
had a correlation coefficient (R2
The Solubility of solid dispersions was determined and compared 
with that of pure drug solubility in distilled water. It was found to be 
an increase in solubility of all the prepared solid dispersions as 
shown in table 1. The maximum increase in solubility was found in 
the F7 formulation that was prepared by solvent evaporation 
technique employing PVP k30 as a carrier in the ratio of 1:1 with the 
drug. So, here it can be said that PVP k30 is the more effective 
carrier in preparing SDs than PEG 6000. Literature also supports the 
enhancement of solubility of solid dispersions is better with the 
hydrophilic carrier PVP K30 than the PEGs by the solvent method. 
This improved solubility can be attributed to the solubilization effect 
of the carrier, which increases the wetting property of the drug [14].
) of 0.996, a slope of 0.022, and a C-
intercept of–0.012. These results indicated that there is a linear 
relationship between concentration (5–25 μg/ml) and absorbance, 
as shown in fig. 2. As per the literature survey, it is confirmed that 
simvastatin show linearity in the concentration range of 5 to 30 
μg/ml when ethanol is used as a solvent and also as a blank. 
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Fig. 2: Calibration curve of simvastatin 
 
Table 1: Solubility data of pure drug and prepared solid dispersions 
Formulation code *Solubility (mg/ml) 









*Data expressed as mean±standard deviation (SD), n=3 
 
The percentage yield and drug content for different ratios of drug 
and carrier were calculated by using formula and values are shown 
in table 2. The percentage yield values were found to get decreased 
at the higher ratios of the carrier due to the difficulty during sieving. 
Drug content values are found to in the range of 88.75 to 94.89%. 
Low standard deviation between values indicated uniformity of drug 
content in all formulations [19]. In Percentage yield values, the yield 
was high in the F3 batch i.e. 95.23% but drug content was 90.26%. 
In F7 formulation, though the yield is 93.18%, actual drug content 
was found to be higher i.e. 94.89. 
  
Table 2: Percentage yield and drug content of prepared solid dispersions 
Formulation code *Percentage yield *Drug content 
F1 92.11±0.961 89.22±0.003 
F2 92.87±1.023 88.75±0.017 
F3 95.23±1.104 90.26±0.012 
F4 89.08±0.025 93.83±0.007 
F5 92.01±0.725 90.81±0.013 
F6 90.27±1.621 92.48±0.003 
F7 93.18±1.321 94.89±0.002 
F8 91.09±0.984 93.14±0.006 
*Data expressed as mean±standard deviation (SD), n=3 
 
FT-IR spectrum of simvastatin showed peaks of characteristic functional 
groups at wavenumbers 3549.14 cm-1 (free O–H stretching vibrations), 
1705 cm-1 (stretching vibration of ester and lactone carbonyl functional 
groups), and 2877 cm-1, 2955 cm-1 (C–H stretching vibrations) as shown 
in fig 3. FT-IR spectrum of PVP K30 is shown in fig. 4. The major peaks of 
simvastatin were retained in the physical mixture and solid dispersions 
as shown in fig. 5 and fig. 6, respectively. Peaks of-OH Stretch (3566.85 
cm-1
The DSC Thermogram of simvastatin showed a sharp endothermic 
peak at 140 °C temperature as shown in fig. 7. The sharp, intense 
peak indicates the pure crystalline nature of the drug. PVP K30 
showed a wide endotherm in the temperature range of 56-95 °C 
which can be attributed to loss of water due to hygroscopic nature 
[20]. In the physical mixture, both endotherms were observed 
indicating compatibility of drug and PVP K30. Lastly, in SD 
Thermogram, a less sharp peak of the drug was seen or can be said 
to be disappeared as compared to the thermogram of pure drug, but 
a wide endotherm at the range of 50-95 °C indicates entrapping of 
simvastatin in the carrier and confirms the amorphous nature of 
solid dispersion. A decrease in the intensity of the sharp peak of 
simvastatin can be attributed to increased dissolution or 
entrapment of simvastatin in the PVP K30 [21]. 
), carbonyl group (1697.47) are observed to be shifted by some 
difference. The possible reason for shifting is intermolecular hydrogen 
bonding. But, no major difference was observed which indicates the 
compatibility of drug and PVP K30 in solid dispersion. In Solid 
dispersions, the possibility of hydrogen bonding between simvastatin 
and PVP is due to PVP. As PVP has two groups =N, =O that can potentially 
form a hydrogen bond with the drug [15]. 
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Fig. 3: FTIR spectrum of simvastatin 
 
 
Fig. 4: FTIR spectrum of PVP K30 
 
 
Fig. 5: FTIR spectrum of physical mixture of simvastatin and PVP K 30 
 
The In vitro dissolution studies of pure drug, physical mixture, 
and SDs were carried out in phosphate buffer pH 6.8 up to 60 
min. The pure drug showed 48.41% drug release in 60 min 
which indicates a poor dissolution profile. The formulations F1 
to F4 which were prepared by the kneading method showed 
drug release from 84.73 to 93.20% in 60 min which indicated 
enhanced dissolution profile as compared to pure drug. The 
formulations F5 to F8 showed drug release from 94.72 to 
98.60% drug release. F7 formulation showed maximum drug 
release i.e. 98.60% in 60 min which is 2 times greater than pure 
drug. This marked increase in dissolution and solubility can be 
attributed to the reduced, uniform particle size and hydrophilic 
nature of PVP K30. Thus from the above data, it can be said that 
simvastatin PVP SDs show better dissolution profiles compared 
to that of PEG 6000, even at the lowest PVP ratio i.e. (1:1) by 
solvent evaporation method [22]. 
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Fig. 6: FTIR spectrum of solid dispersion of simvastatin and PVP K30 (F7 formulation) 
 
 
Fig. 7: Overlay of DSC thermograms of (a) Simvastatin, (b) PVP K30, (c) Physical mixture of simvastatin and PVP K30, (d) Solid dispersion 
of simvastatin and PVP K30 (1:1) 
 
Table 3: Dissolution data of prepared solid dispersions 
Time 
(in min) 
*Percentage (%) drug release 
Drug F1 F2 F3 F4 F5 F6 F7 F8 
0 1.088±1 1.914±1 1.783±2 2.871±1 3.362±1 1.726±1 1.669±2 8.762±1 7.862±1 
5 2.299±1 3.051±2 3.984±1 8.181±2 9.981±2 6.676±2 6.520±1 20.23±1 16.38±1 
10 3.878±1 6.054±1 9.154±1 16.99±1 21.11±1 18.42±1 19.05±2 31.83±2 27.58±2 
20 7.601±2 14.90±2 21.53±2 30.83±1 33.40±2 31.27±1 34.48±1 43.88±2 39.94±2± 
30 16.16±2 30.39±2 36.85±2 48.16±2 47.06±2 44.51±2 50.61±2 56.46±2 52.60±1 
40 26.60±1 46.21±2 51.00±1 67.27±2 64.33±3 60.09±2 68.27±1 69.56±2 66.62±1 
50 37.35±1 65.13±2 67.97±1 87.04±2 82.97±2 77.17±2 86.71±2 86.48±1 80.91±2 
60 48.41±1 84.73±1 86.43±1 90.69±1 93.20±2 95.81±1 94.72±1 98.60±1 96.48±1 
 *Data expressed as mean±standard deviation (SD), n=3 
 
 
Fig. 8: In vitro dissolution profile of a pure drug, physical mixture, and solid dispersions (F1 to F8) 
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The in vitro dissolution data is given in table 3. By using Dissolution 
data, a graph is plotted between Cumulative % drug release and time 
which is shown in fig. 8. As per solubility and dissolution data, it can 
be confirmed that solvent evaporation is the best method as 
compared to kneading and the physical mixture method for the 
preparation of solid dispersions. In fig. 9, dissolution profiles of pure 
drug, physical mixture, F3, and F7 formulations are shown which 
indicates enhancement of simvastatin dissolution rate by a solvent 
evaporation method (F7 formulation dissolution profile). In the 
literature review of cefixime solid dispersions, the maximum 
increase in the dissolution rate was obtained with the dispersions 
prepared through the solvent evaporation method than the 
kneading method, and comparatively faster dissolution rates were 
obtained than that of the pure drug [23]. 
 
 
Fig. 9: In vitro dissolution profile of a pure drug, physical mixture, F3 and F7 formulation 
 
F7 was found to be the best formulation so drug release kinetics was 
obtained from in vitro dissolution data and shown in table 4. It was 
found to follow a zero-order kinetic model with an R2
 
of 0.986 as 
shown in fig. 10. 
Table 4: Correlation coefficient values for optimized formulation 
Formulation 
code 
Correlation coefficient (r2) values 
Zero order model Korsemeyer peppas model Higuchi model Hixson crowell model First order model 
F7 0.986 0.982 0.970 0.965 0.937 
 
 
Fig. 10: Dissolution release kinetics (a) Zero-order model, (b) Korsemeyer peppas plot, (c) Higuchi model, (d) Hixson crowell model, (e) 
First order model 
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CONCLUSION 
The solid dispersions of simvastatin prepared by kneading and 
solvent evaporation method with two different carriers (PEG 6000, 
PVP K30) showed considerably higher drug dissolution in 
comparison with pure drug. The result showed that the solid 
dispersions prepared with the solvent evaporation method give a 
higher dissolution rate than the kneading method. Amongst the 
carrier used, PVP K30 showed significant enhancement in solubility 
and dissolution. SD of drug and PVP K30 in the ratio of 1:1 gave a 
higher intrinsic dissolution rate. The DSC Thermogram of optimized 
solid dispersion batch (F7) showed entrapment of drug in a carrier 
matrix and confirmed amorphous nature. PVP K30 does not show 
any incompatibility with simvastatin and that was confirmed by FT-
IR analysis. Thus, the present research concluded that solid 
dispersion technology can be used effectively to enhance the 
solubility and also dissolution rate of the poorly water-soluble drug 
simvastatin. 
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